Recombinant mumps virus as a cancer therapeutic agent

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21 st century, the interest to pursue mumps virus for cancer treatment slowly faded away. Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. We have obtained the Urabe strain of mumps virus from Osaka University, Japan, which was used in the earlier human clinical trials. In this report we describe the development of a reverse genetics system from a major isolate of this Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. We present initial data demonstrating these recombinant mumps viruses have oncolytic activity against tumor cell lines in vitro and some efficacy in preliminary pilot animal tumor models.

Original languageEnglish (US)
Article number16019
JournalMolecular Therapy - Oncolytics
Volume3
DOIs
StatePublished - Aug 10 2016

Fingerprint

Mumps virus
Neoplasms
Therapeutics
Japan
Oncolytic Virotherapy
Paramyxoviridae
Clinical Trials
Reverse Genetics
Tumor Cell Line
Transgenes
Animal Models

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Pharmacology (medical)

Cite this

Recombinant mumps virus as a cancer therapeutic agent. / Ammayappan, Arun; Russell, Stephen J; Federspiel, Mark J.

In: Molecular Therapy - Oncolytics, Vol. 3, 16019, 10.08.2016.

Research output: Contribution to journalArticle

@article{e586721cfd5a488ab2d9f497796fad55,
title = "Recombinant mumps virus as a cancer therapeutic agent",
abstract = "Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21 st century, the interest to pursue mumps virus for cancer treatment slowly faded away. Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. We have obtained the Urabe strain of mumps virus from Osaka University, Japan, which was used in the earlier human clinical trials. In this report we describe the development of a reverse genetics system from a major isolate of this Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. We present initial data demonstrating these recombinant mumps viruses have oncolytic activity against tumor cell lines in vitro and some efficacy in preliminary pilot animal tumor models.",
author = "Arun Ammayappan and Russell, {Stephen J} and Federspiel, {Mark J}",
year = "2016",
month = "8",
day = "10",
doi = "10.1038/mto.2016.19",
language = "English (US)",
volume = "3",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Recombinant mumps virus as a cancer therapeutic agent

AU - Ammayappan, Arun

AU - Russell, Stephen J

AU - Federspiel, Mark J

PY - 2016/8/10

Y1 - 2016/8/10

N2 - Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21 st century, the interest to pursue mumps virus for cancer treatment slowly faded away. Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. We have obtained the Urabe strain of mumps virus from Osaka University, Japan, which was used in the earlier human clinical trials. In this report we describe the development of a reverse genetics system from a major isolate of this Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. We present initial data demonstrating these recombinant mumps viruses have oncolytic activity against tumor cell lines in vitro and some efficacy in preliminary pilot animal tumor models.

AB - Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21 st century, the interest to pursue mumps virus for cancer treatment slowly faded away. Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. We have obtained the Urabe strain of mumps virus from Osaka University, Japan, which was used in the earlier human clinical trials. In this report we describe the development of a reverse genetics system from a major isolate of this Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. We present initial data demonstrating these recombinant mumps viruses have oncolytic activity against tumor cell lines in vitro and some efficacy in preliminary pilot animal tumor models.

UR - http://www.scopus.com/inward/record.url?scp=85006201951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006201951&partnerID=8YFLogxK

U2 - 10.1038/mto.2016.19

DO - 10.1038/mto.2016.19

M3 - Article

AN - SCOPUS:85006201951

VL - 3

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

M1 - 16019

ER -